search
Back to results

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Primary Purpose

Ovarian Neoplasms, Peritoneal Neoplasms

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo
Paclitaxel
BIBF 1120
Carboplatin
Paclitaxel
Carboplatin
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ovarian Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria:

  • first diagnosis of histologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
  • International Federation of Gynecology and Obstetrics (FIGO) Stages IIB - IV
  • females, age 18 years or older
  • life expectancy of at least 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  • prior surgery, defined as either (a) debulking surgery with maximum surgical effort at cytoreduction with the goal of no residual disease or (b) biopsy or limited surgery in patients with stage IV disease for whom surgical debulking was not considered appropriate, if diagnosis is confirmed by histology and no surgery is planned prior to disease progression (including interval debulking surgery)
  • patient has given written informed consent which must be consistent with the International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local legislation
  • planned application of first dose of chemotherapy after wound healing, but no later than 10 weeks after surgery

Exclusion criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum
  • planned surgery within 124 weeks after randomisation in this trial, including interval debulking surgery
  • clinically relevant non-healing wound, ulcer or bone fracture
  • clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration
  • brain metastases
  • pre-existing sensory or motor neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher, except due to trauma
  • history of major thromboembolic event
  • known inherited or acquired bleeding disorder
  • significant cardiovascular diseases
  • clinically relevant pericardial effusion
  • history of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months
  • inadequate safety laboratory values
  • serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV)
  • poorly controlled diabetes mellitus or other contraindication to high dose corticosteroid therapy
  • gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • other malignancy diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included if adequately treated: non-melanomatous skin cancer, cervical carcinoma in situ, carcinoma in situ of the breast, low risk endometrial cancer
  • prior systemic therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy)
  • prior systemic cytotoxic chemotherapy
  • prior treatment with BIBF 1120 or any other angiogenesis inhibitor
  • prior radiotherapy
  • serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration
  • Women of childbearing potential who are sexually active and not using a highly effective method of birth control during the trial and for at least twelve months after the end of active therapy.
  • pregnancy or breast feeding
  • psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
  • active alcohol or drug abuse
  • patients unable to comply with the protocol
  • any contraindications for therapy with paclitaxel or carboplatin
  • treatment with other investigational drugs or participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial

Sites / Locations

  • 1199.15.10113 Boehringer Ingelheim Investigational Site
  • 1199.15.10030 Boehringer Ingelheim Investigational Site
  • 1199.15.10001 Boehringer Ingelheim Investigational Site
  • 1199.15.10005 Boehringer Ingelheim Investigational Site
  • 1199.15.10028 Boehringer Ingelheim Investigational Site
  • 1199.15.10014 Boehringer Ingelheim Investigational Site
  • 1199.15.10010 Boehringer Ingelheim Investigational Site
  • 1199.15.10004 Boehringer Ingelheim Investigational Site
  • 1199.15.10011 Boehringer Ingelheim Investigational Site
  • 1199.15.10003 Boehringer Ingelheim Investigational Site
  • 1199.15.10017 Boehringer Ingelheim Investigational Site
  • 1199.15.10103 Boehringer Ingelheim Investigational Site
  • 1199.15.10002 Boehringer Ingelheim Investigational Site
  • 1199.15.10012 Boehringer Ingelheim Investigational Site
  • 1199.15.10020 Boehringer Ingelheim Investigational Site
  • 1199.15.10019 Boehringer Ingelheim Investigational Site
  • 1199.15.10024 Boehringer Ingelheim Investigational Site
  • 1199.15.10025 Boehringer Ingelheim Investigational Site
  • 1199.15.10029 Boehringer Ingelheim Investigational Site
  • 1199.15.10021 Boehringer Ingelheim Investigational Site
  • 1199.15.10013 Boehringer Ingelheim Investigational Site
  • 1199.15.10016 Boehringer Ingelheim Investigational Site
  • 1199.15.10008 Boehringer Ingelheim Investigational Site
  • 1199.15.10102 Boehringer Ingelheim Investigational Site
  • 1199.15.10006 Boehringer Ingelheim Investigational Site
  • 1199.15.10104 Boehringer Ingelheim Investigational Site
  • 1199.15.10100 Boehringer Ingelheim Investigational Site
  • 1199.15.10107 Boehringer Ingelheim Investigational Site
  • 1199.15.10108 Boehringer Ingelheim Investigational Site
  • 1199.15.10110 Boehringer Ingelheim Investigational Site
  • 1199.15.10007 Boehringer Ingelheim Investigational Site
  • 1199.15.10105 Boehringer Ingelheim Investigational Site
  • 1199.15.10112 Boehringer Ingelheim Investigational Site
  • 1199.15.61006 Boehringer Ingelheim Investigational Site
  • 1199.15.61001 Boehringer Ingelheim Investigational Site
  • 1199.15.61004 Boehringer Ingelheim Investigational Site
  • 1199.15.61003 Boehringer Ingelheim Investigational Site
  • 1199.15.61005 Boehringer Ingelheim Investigational Site
  • 1199.15.61007 Boehringer Ingelheim Investigational Site
  • 1199.15.61002 Boehringer Ingelheim Investigational Site
  • 1199.15.43003 Boehringer Ingelheim Investigational Site
  • 1199.15.43001 Boehringer Ingelheim Investigational Site
  • 1199.15.43011 Boehringer Ingelheim Investigational Site
  • 1199.15.43007 Boehringer Ingelheim Investigational Site
  • 1199.15.43005 Boehringer Ingelheim Investigational Site
  • 1199.15.43010 Boehringer Ingelheim Investigational Site
  • 1199.15.43013 Boehringer Ingelheim Investigational Site
  • 1199.15.43002 Boehringer Ingelheim Investigational Site
  • 1199.15.43012 Boehringer Ingelheim Investigational Site
  • 1199.15.32010 Boehringer Ingelheim Investigational Site
  • 1199.15.32012 Boehringer Ingelheim Investigational Site
  • 1199.15.32003 Boehringer Ingelheim Investigational Site
  • 1199.15.32001 Boehringer Ingelheim Investigational Site
  • 1199.15.32007 Boehringer Ingelheim Investigational Site
  • 1199.15.32008 Boehringer Ingelheim Investigational Site
  • 1199.15.11005 Boehringer Ingelheim Investigational Site
  • 1199.15.11004 Boehringer Ingelheim Investigational Site
  • 1199.15.11008 Boehringer Ingelheim Investigational Site
  • 1199.15.11009 Boehringer Ingelheim Investigational Site
  • 1199.15.11003 Boehringer Ingelheim Investigational Site
  • 1199.15.11006 Boehringer Ingelheim Investigational Site
  • 1199.15.11001 Boehringer Ingelheim Investigational Site
  • 1199.15.42002 Boehringer Ingelheim Investigational Site
  • 1199.15.42003 Boehringer Ingelheim Investigational Site
  • 1199.15.42001 Boehringer Ingelheim Investigational Site
  • 1199.15.45004 Boehringer Ingelheim Investigational Site
  • 1199.15.45002 Boehringer Ingelheim Investigational Site
  • 1199.15.45005 Boehringer Ingelheim Investigational Site
  • 1199.15.45001 Boehringer Ingelheim Investigational Site
  • 1199.15.45003 Boehringer Ingelheim Investigational Site
  • 1199.15.35801 Boehringer Ingelheim Investigational Site
  • 1199.15.35804 Boehringer Ingelheim Investigational Site
  • 1199.15.35805 Boehringer Ingelheim Investigational Site
  • 1199.15.35803 Boehringer Ingelheim Investigational Site
  • 1199.15.35802 Boehringer Ingelheim Investigational Site
  • 1199.15.33047 Boehringer Ingelheim Investigational Site
  • 1199.15.33035 Boehringer Ingelheim Investigational Site
  • 1199.15.33055 Boehringer Ingelheim Investigational Site
  • 1199.15.33003 Boehringer Ingelheim Investigational Site
  • 1199.15.33004 Boehringer Ingelheim Investigational Site
  • 1199.15.33006 Boehringer Ingelheim Investigational Site
  • 1199.15.33025 Boehringer Ingelheim Investigational Site
  • 1199.15.33048 Boehringer Ingelheim Investigational Site
  • 1199.15.33042 Boehringer Ingelheim Investigational Site
  • 1199.15.33037 Boehringer Ingelheim Investigational Site
  • 1199.15.33008 Boehringer Ingelheim Investigational Site
  • 1199.15.33009 Boehringer Ingelheim Investigational Site
  • 1199.15.33020 Boehringer Ingelheim Investigational Site
  • 1199.15.33011 Boehringer Ingelheim Investigational Site
  • 1199.15.33021 Boehringer Ingelheim Investigational Site
  • 1199.15.33012 Boehringer Ingelheim Investigational Site
  • 1199.15.33052 Boehringer Ingelheim Investigational Site
  • 1199.15.33053 Boehringer Ingelheim Investigational Site
  • 1199.15.33038 Boehringer Ingelheim Investigational Site
  • 1199.15.33013 Boehringer Ingelheim Investigational Site
  • 1199.15.33015 Boehringer Ingelheim Investigational Site
  • 1199.15.33027 Boehringer Ingelheim Investigational Site
  • 1199.15.33001 Boehringer Ingelheim Investigational Site
  • 1199.15.33051 Boehringer Ingelheim Investigational Site
  • 1199.15.33030 Boehringer Ingelheim Investigational Site
  • 1199.15.33045 Boehringer Ingelheim Investigational Site
  • 1199.15.33033 Boehringer Ingelheim Investigational Site
  • 1199.15.33018 Boehringer Ingelheim Investigational Site
  • 1199.15.33039 Boehringer Ingelheim Investigational Site
  • 1199.15.33031 Boehringer Ingelheim Investigational Site
  • 1199.15.33050 Boehringer Ingelheim Investigational Site
  • 1199.15.49040 Boehringer Ingelheim Investigational Site
  • 1199.15.49070 Boehringer Ingelheim Investigational Site
  • 1199.15.49086 Boehringer Ingelheim Investigational Site
  • 1199.15.49002 Boehringer Ingelheim Investigational Site
  • 1199.15.49039 Boehringer Ingelheim Investigational Site
  • 1199.15.49041 Boehringer Ingelheim Investigational Site
  • 1199.15.49004 Boehringer Ingelheim Investigational Site
  • 1199.15.49042 Boehringer Ingelheim Investigational Site
  • 1199.15.49071 Boehringer Ingelheim Investigational Site
  • 1199.15.49081 Boehringer Ingelheim Investigational Site
  • 1199.15.49043 Boehringer Ingelheim Investigational Site
  • 1199.15.49005 Boehringer Ingelheim Investigational Site
  • 1199.15.49006 Boehringer Ingelheim Investigational Site
  • 1199.15.49007 Boehringer Ingelheim Investigational Site
  • 1199.15.49067 Boehringer Ingelheim Investigational Site
  • 1199.15.49008 Boehringer Ingelheim Investigational Site
  • 1199.15.49009 Boehringer Ingelheim Investigational Site
  • 1199.15.49010 Boehringer Ingelheim Investigational Site
  • 1199.15.49066 Boehringer Ingelheim Investigational Site
  • 1199.15.49089 Boehringer Ingelheim Investigational Site
  • 1199.15.49045 Boehringer Ingelheim Investigational Site
  • 1199.15.49011 Boehringer Ingelheim Investigational Site
  • 1199.15.49068 Boehringer Ingelheim Investigational Site
  • 1199.15.49083 Boehringer Ingelheim Investigational Site
  • 1199.15.49046 Boehringer Ingelheim Investigational Site
  • 1199.15.49012 Boehringer Ingelheim Investigational Site
  • 1199.15.49064 Boehringer Ingelheim Investigational Site
  • 1199.15.49076 Boehringer Ingelheim Investigational Site
  • 1199.15.49014 Boehringer Ingelheim Investigational Site
  • 1199.15.49015 Boehringer Ingelheim Investigational Site
  • 1199.15.49084 Boehringer Ingelheim Investigational Site
  • 1199.15.49073 Boehringer Ingelheim Investigational Site
  • 1199.15.49095 Boehringer Ingelheim Investigational Site
  • 1199.15.49080 Boehringer Ingelheim Investigational Site
  • 1199.15.49047 Boehringer Ingelheim Investigational Site
  • 1199.15.49016 Boehringer Ingelheim Investigational Site
  • 1199.15.49017 Boehringer Ingelheim Investigational Site
  • 1199.15.49062 Boehringer Ingelheim Investigational Site
  • 1199.15.49018 Boehringer Ingelheim Investigational Site
  • 1199.15.49087 Boehringer Ingelheim Investigational Site
  • 1199.15.49019 Boehringer Ingelheim Investigational Site
  • 1199.15.49020 Boehringer Ingelheim Investigational Site
  • 1199.15.49021 Boehringer Ingelheim Investigational Site
  • 1199.15.49022 Boehringer Ingelheim Investigational Site
  • 1199.15.49023 Boehringer Ingelheim Investigational Site
  • 1199.15.49024 Boehringer Ingelheim Investigational Site
  • 1199.15.49025 Boehringer Ingelheim Investigational Site
  • 1199.15.49026 Boehringer Ingelheim Investigational Site
  • 1199.15.49027 Boehringer Ingelheim Investigational Site
  • 1199.15.49048 Boehringer Ingelheim Investigational Site
  • 1199.15.49065 Boehringer Ingelheim Investigational Site
  • 1199.15.49029 Boehringer Ingelheim Investigational Site
  • 1199.15.49082 Boehringer Ingelheim Investigational Site
  • 1199.15.49030 Boehringer Ingelheim Investigational Site
  • 1199.15.49061 Boehringer Ingelheim Investigational Site
  • 1199.15.49050 Boehringer Ingelheim Investigational Site
  • 1199.15.49051 Boehringer Ingelheim Investigational Site
  • 1199.15.49052 Boehringer Ingelheim Investigational Site
  • 1199.15.49054 Boehringer Ingelheim Investigational Site
  • 1199.15.49031 Boehringer Ingelheim Investigational Site
  • 1199.15.49055 Boehringer Ingelheim Investigational Site
  • 1199.15.49092 Boehringer Ingelheim Investigational Site
  • 1199.15.49063 Boehringer Ingelheim Investigational Site
  • 1199.15.49093 Boehringer Ingelheim Investigational Site
  • 1199.15.49033 Boehringer Ingelheim Investigational Site
  • 1199.15.49056 Boehringer Ingelheim Investigational Site
  • 1199.15.49090 Boehringer Ingelheim Investigational Site
  • 1199.15.49079 Boehringer Ingelheim Investigational Site
  • 1199.15.49034 Boehringer Ingelheim Investigational Site
  • 1199.15.49057 Boehringer Ingelheim Investigational Site
  • 1199.15.49035 Boehringer Ingelheim Investigational Site
  • 1199.15.49058 Boehringer Ingelheim Investigational Site
  • 1199.15.49085 Boehringer Ingelheim Investigational Site
  • 1199.15.49001 Boehringer Ingelheim Investigational Site
  • 1199.15.49036 Boehringer Ingelheim Investigational Site
  • 1199.15.49059 Boehringer Ingelheim Investigational Site
  • 1199.15.49037 Boehringer Ingelheim Investigational Site
  • 1199.15.49060 Boehringer Ingelheim Investigational Site
  • 1199.15.30001 Boehringer Ingelheim Investigational Site
  • 1199.15.30003 Boehringer Ingelheim Investigational Site
  • 1199.15.30002 Boehringer Ingelheim Investigational Site
  • 1199.15.30005 Boehringer Ingelheim Investigational Site
  • 1199.15.30004 Boehringer Ingelheim Investigational Site
  • 1199.15.39027 Boehringer Ingelheim Investigational Site
  • 1199.15.39002 Boehringer Ingelheim Investigational Site
  • 1199.15.39003 Boehringer Ingelheim Investigational Site
  • 1199.15.39004 Boehringer Ingelheim Investigational Site
  • 1199.15.39005 Boehringer Ingelheim Investigational Site
  • 1199.15.39029 Boehringer Ingelheim Investigational Site
  • 1199.15.39040 Boehringer Ingelheim Investigational Site
  • 1199.15.39007 Boehringer Ingelheim Investigational Site
  • 1199.15.39008 Boehringer Ingelheim Investigational Site
  • 1199.15.39039 Boehringer Ingelheim Investigational Site
  • 1199.15.39017 Boehringer Ingelheim Investigational Site
  • 1199.15.39037 Boehringer Ingelheim Investigational Site
  • 1199.15.39009 Boehringer Ingelheim Investigational Site
  • 1199.15.39033 Boehringer Ingelheim Investigational Site
  • 1199.15.39021 Boehringer Ingelheim Investigational Site
  • 1199.15.39028 Boehringer Ingelheim Investigational Site
  • 1199.15.39036 Boehringer Ingelheim Investigational Site
  • 1199.15.39010 Boehringer Ingelheim Investigational Site
  • 1199.15.39026 Boehringer Ingelheim Investigational Site
  • 1199.15.39001 Boehringer Ingelheim Investigational Site
  • 1199.15.39022 Boehringer Ingelheim Investigational Site
  • 1199.15.39011 Boehringer Ingelheim Investigational Site
  • 1199.15.39031 Boehringer Ingelheim Investigational Site
  • 1199.15.39023 Boehringer Ingelheim Investigational Site
  • 1199.15.39012 Boehringer Ingelheim Investigational Site
  • 1199.15.39024 Boehringer Ingelheim Investigational Site
  • 1199.15.39013 Boehringer Ingelheim Investigational Site
  • 1199.15.39014 Boehringer Ingelheim Investigational Site
  • 1199.15.39034 Boehringer Ingelheim Investigational Site
  • 1199.15.39030 Boehringer Ingelheim Investigational Site
  • 1199.15.39018 Boehringer Ingelheim Investigational Site
  • 1199.15.39006 Boehringer Ingelheim Investigational Site
  • 1199.15.39019 Boehringer Ingelheim Investigational Site
  • 1199.15.39020 Boehringer Ingelheim Investigational Site
  • 1199.15.39032 Boehringer Ingelheim Investigational Site
  • 1199.15.31009 Boehringer Ingelheim Investigational Site
  • 1199.15.31005 Boehringer Ingelheim Investigational Site
  • 1199.15.31004 Boehringer Ingelheim Investigational Site
  • 1199.15.31003 Boehringer Ingelheim Investigational Site
  • 1199.15.31006 Boehringer Ingelheim Investigational Site
  • 1199.15.31002 Boehringer Ingelheim Investigational Site
  • 1199.15.47003 Boehringer Ingelheim Investigational Site
  • 1199.15.47001 Boehringer Ingelheim Investigational Site
  • 1199.15.47002 Boehringer Ingelheim Investigational Site
  • 1199.15.47004 Boehringer Ingelheim Investigational Site
  • 1199.15.48003 Boehringer Ingelheim Investigational Site
  • 1199.15.48006 Boehringer Ingelheim Investigational Site
  • 1199.15.48001 Boehringer Ingelheim Investigational Site
  • 1199.15.35102 Boehringer Ingelheim Investigational Site
  • 1199.15.35104 Boehringer Ingelheim Investigational Site
  • 1199.15.35101 Instituto Portugues de Oncologia Lisboa Francisco Gentil
  • 1199.15.35106 Boehringer Ingelheim Investigational Site
  • 1199.15.35108 Boehringer Ingelheim Investigational Site
  • 1199.15.35105 Boehringer Ingelheim Investigational Site
  • 1199.15.35109 Boehringer Ingelheim Investigational Site
  • 1199.15.70006 Boehringer Ingelheim Investigational Site
  • 1199.15.70005 Boehringer Ingelheim Investigational Site
  • 1199.15.70007 Boehringer Ingelheim Investigational Site
  • 1199.15.70001 Boehringer Ingelheim Investigational Site
  • 1199.15.70002 Boehringer Ingelheim Investigational Site
  • 1199.15.42101 Boehringer Ingelheim Investigational Site
  • 1199.15.42105 Boehringer Ingelheim Investigational Site
  • 1199.15.42106 Boehringer Ingelheim Investigational Site
  • 1199.15.42103 Boehringer Ingelheim Investigational Site
  • 1199.15.42104 Boehringer Ingelheim Investigational Site
  • 1199.15.42102 Boehringer Ingelheim Investigational Site
  • 1199.15.34001 Boehringer Ingelheim Investigational Site
  • 1199.15.34003 Boehringer Ingelheim Investigational Site
  • 1199.15.34006 Boehringer Ingelheim Investigational Site
  • 1199.15.34004 Boehringer Ingelheim Investigational Site
  • 1199.15.34002 Boehringer Ingelheim Investigational Site
  • 1199.15.34010 Boehringer Ingelheim Investigational Site
  • 1199.15.34005 Boehringer Ingelheim Investigational Site
  • 1199.15.34009 Boehringer Ingelheim Investigational Site
  • 1199.15.46005 Boehringer Ingelheim Investigational Site
  • 1199.15.46001 Boehringer Ingelheim Investigational Site
  • 1199.15.46002 Boehringer Ingelheim Investigational Site
  • 1199.15.46004 Boehringer Ingelheim Investigational Site
  • 1199.15.46003 Boehringer Ingelheim Investigational Site
  • 1199.15.38006 Boehringer Ingelheim Investigational Site
  • 1199.15.38005 Boehringer Ingelheim Investigational Site
  • 1199.15.38004 Boehringer Ingelheim Investigational Site
  • 1199.15.38002 Boehringer Ingelheim Investigational Site
  • 1199.15.38003 Boehringer Ingelheim Investigational Site
  • 1199.15.44006 Boehringer Ingelheim Investigational Site
  • 1199.15.44007 Boehringer Ingelheim Investigational Site
  • 1199.15.44003 Boehringer Ingelheim Investigational Site
  • 1199.15.44001 Boehringer Ingelheim Investigational Site
  • 1199.15.44005 Boehringer Ingelheim Investigational Site
  • 1199.15.44004 Boehringer Ingelheim Investigational Site
  • 1199.15.44002 Boehringer Ingelheim Investigational Site
  • 1199.15.44008 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

BIBF 1120

Placebo

Arm Description

patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel

patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel

Outcomes

Primary Outcome Measures

PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.
Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).
Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.

Secondary Outcome Measures

PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).
Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).
Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Overall Survival
Overall survival is defined as time from randomization to date of death (irrespective of reason). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Time to CA-125 Tumour Marker Progression
Time to tumour-marker progression was defined as the time from randomisation until the date when Carbohydrate (cancer) antigen (CA-125) values increased to higher than twice the nadir value. CA-125 >=2 x nadir in case nadir value > Upper limit of normal (ULN) or CA-125 >=2 x ULN in case nadir value <= ULN.
Objective Response Based on Investigator Assessment
Objective tumour response defined as either complete response [CR] or partial response [PR] in patients with at least 1 target lesion reported at baseline
Change in Abdominal/Gastro-intestinal Symptoms Over Time
Change in abdominal/gastro-intestinal over time was calculated on symptoms (scale composite of items 31 to 37 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Ovarian Cancer 28 (EORTC QLQ OV-28). As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/severe level of symptomatology). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).
Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.
Change in Global Health Status/ Quality of life (QoL) over time was calculated on Global Health Status/QoL scale (composite of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) as a general measure. As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/healthy level of functioning). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).

Full Information

First Posted
November 9, 2009
Last Updated
November 3, 2017
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT01015118
Brief Title
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Official Title
Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
November 17, 2009 (Actual)
Primary Completion Date
April 1, 2013 (Actual)
Study Completion Date
September 15, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Neoplasms, Peritoneal Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
1366 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BIBF 1120
Arm Type
Experimental
Arm Description
patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
comparator to BIBF 1120
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Paclitaxel (standard chemo-therapy)
Intervention Type
Drug
Intervention Name(s)
BIBF 1120
Intervention Description
comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Carboplatin (standard chemo-therapy)
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Paclitaxel (standard chemo-therapy)
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Carboplatin (standard chemo-therapy)
Primary Outcome Measure Information:
Title
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.
Description
Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Time Frame
First drug administration to date of disease progression or death whichever occurs first , upto 29 months
Title
PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).
Description
Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Time Frame
First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months
Secondary Outcome Measure Information:
Title
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).
Description
Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Time Frame
First drug administration to date of disease progression or death whichever occurs first , upto 29 months
Title
PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).
Description
Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Time Frame
First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months
Title
Overall Survival
Description
Overall survival is defined as time from randomization to date of death (irrespective of reason). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm.
Time Frame
First drug administration to date of death until final DBL 26September16, upto 62 months
Title
Time to CA-125 Tumour Marker Progression
Description
Time to tumour-marker progression was defined as the time from randomisation until the date when Carbohydrate (cancer) antigen (CA-125) values increased to higher than twice the nadir value. CA-125 >=2 x nadir in case nadir value > Upper limit of normal (ULN) or CA-125 >=2 x ULN in case nadir value <= ULN.
Time Frame
First drug administration until final DBL 26September16, upto 62 months
Title
Objective Response Based on Investigator Assessment
Description
Objective tumour response defined as either complete response [CR] or partial response [PR] in patients with at least 1 target lesion reported at baseline
Time Frame
First drug administration until final DBL 26September16, upto 62 months
Title
Change in Abdominal/Gastro-intestinal Symptoms Over Time
Description
Change in abdominal/gastro-intestinal over time was calculated on symptoms (scale composite of items 31 to 37 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Ovarian Cancer 28 (EORTC QLQ OV-28). As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/severe level of symptomatology). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).
Time Frame
First drug administration until final DBL 26September16, upto 62 months
Title
Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.
Description
Change in Global Health Status/ Quality of life (QoL) over time was calculated on Global Health Status/QoL scale (composite of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) as a general measure. As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/healthy level of functioning). Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6).
Time Frame
First drug administration until final DBL 26September16, upto 62 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: first diagnosis of histologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer International Federation of Gynecology and Obstetrics (FIGO) Stages IIB - IV females, age 18 years or older life expectancy of at least 6 months Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 prior surgery, defined as either (a) debulking surgery with maximum surgical effort at cytoreduction with the goal of no residual disease or (b) biopsy or limited surgery in patients with stage IV disease for whom surgical debulking was not considered appropriate, if diagnosis is confirmed by histology and no surgery is planned prior to disease progression (including interval debulking surgery) patient has given written informed consent which must be consistent with the International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local legislation planned application of first dose of chemotherapy after wound healing, but no later than 10 weeks after surgery Exclusion criteria: histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum planned surgery within 124 weeks after randomisation in this trial, including interval debulking surgery clinically relevant non-healing wound, ulcer or bone fracture clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration brain metastases pre-existing sensory or motor neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher, except due to trauma history of major thromboembolic event known inherited or acquired bleeding disorder significant cardiovascular diseases clinically relevant pericardial effusion history of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months inadequate safety laboratory values serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) poorly controlled diabetes mellitus or other contraindication to high dose corticosteroid therapy gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug other malignancy diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included if adequately treated: non-melanomatous skin cancer, cervical carcinoma in situ, carcinoma in situ of the breast, low risk endometrial cancer prior systemic therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy) prior systemic cytotoxic chemotherapy prior treatment with BIBF 1120 or any other angiogenesis inhibitor prior radiotherapy serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration Women of childbearing potential who are sexually active and not using a highly effective method of birth control during the trial and for at least twelve months after the end of active therapy. pregnancy or breast feeding psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule active alcohol or drug abuse patients unable to comply with the protocol any contraindications for therapy with paclitaxel or carboplatin treatment with other investigational drugs or participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1199.15.10113 Boehringer Ingelheim Investigational Site
City
Tucson
State/Province
Arizona
Country
United States
Facility Name
1199.15.10030 Boehringer Ingelheim Investigational Site
City
Long Beach
State/Province
California
Country
United States
Facility Name
1199.15.10001 Boehringer Ingelheim Investigational Site
City
Santa Rosa
State/Province
California
Country
United States
Facility Name
1199.15.10005 Boehringer Ingelheim Investigational Site
City
Englewood
State/Province
Colorado
Country
United States
Facility Name
1199.15.10028 Boehringer Ingelheim Investigational Site
City
New Haven
State/Province
Connecticut
Country
United States
Facility Name
1199.15.10014 Boehringer Ingelheim Investigational Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
1199.15.10010 Boehringer Ingelheim Investigational Site
City
Augusta
State/Province
Georgia
Country
United States
Facility Name
1199.15.10004 Boehringer Ingelheim Investigational Site
City
Savannah
State/Province
Georgia
Country
United States
Facility Name
1199.15.10011 Boehringer Ingelheim Investigational Site
City
Louisville
State/Province
Kentucky
Country
United States
Facility Name
1199.15.10003 Boehringer Ingelheim Investigational Site
City
Marrero
State/Province
Louisiana
Country
United States
Facility Name
1199.15.10017 Boehringer Ingelheim Investigational Site
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
1199.15.10103 Boehringer Ingelheim Investigational Site
City
Minneapolis
State/Province
Minnesota
Country
United States
Facility Name
1199.15.10002 Boehringer Ingelheim Investigational Site
City
New York
State/Province
New York
Country
United States
Facility Name
1199.15.10012 Boehringer Ingelheim Investigational Site
City
Charlotte
State/Province
North Carolina
Country
United States
Facility Name
1199.15.10020 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
1199.15.10019 Boehringer Ingelheim Investigational Site
City
Bismarck
State/Province
North Dakota
Country
United States
Facility Name
1199.15.10024 Boehringer Ingelheim Investigational Site
City
Canton
State/Province
Ohio
Country
United States
Facility Name
1199.15.10025 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
1199.15.10029 Boehringer Ingelheim Investigational Site
City
Cleveland
State/Province
Ohio
Country
United States
Facility Name
1199.15.10021 Boehringer Ingelheim Investigational Site
City
Portland
State/Province
Oregon
Country
United States
Facility Name
1199.15.10013 Boehringer Ingelheim Investigational Site
City
Abington
State/Province
Pennsylvania
Country
United States
Facility Name
1199.15.10016 Boehringer Ingelheim Investigational Site
City
Allentown
State/Province
Pennsylvania
Country
United States
Facility Name
1199.15.10008 Boehringer Ingelheim Investigational Site
City
Providence
State/Province
Rhode Island
Country
United States
Facility Name
1199.15.10102 Boehringer Ingelheim Investigational Site
City
Greenville
State/Province
South Carolina
Country
United States
Facility Name
1199.15.10006 Boehringer Ingelheim Investigational Site
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
1199.15.10104 Boehringer Ingelheim Investigational Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
1199.15.10100 Boehringer Ingelheim Investigational Site
City
Bedford
State/Province
Texas
Country
United States
Facility Name
1199.15.10107 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1199.15.10108 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1199.15.10110 Boehringer Ingelheim Investigational Site
City
Fort Worth
State/Province
Texas
Country
United States
Facility Name
1199.15.10007 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1199.15.10105 Boehringer Ingelheim Investigational Site
City
Spokane
State/Province
Washington
Country
United States
Facility Name
1199.15.10112 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
Washington
Country
United States
Facility Name
1199.15.61006 Boehringer Ingelheim Investigational Site
City
Camperdown
State/Province
New South Wales
Country
Australia
Facility Name
1199.15.61001 Boehringer Ingelheim Investigational Site
City
Waratah
State/Province
New South Wales
Country
Australia
Facility Name
1199.15.61004 Boehringer Ingelheim Investigational Site
City
Herston
State/Province
Queensland
Country
Australia
Facility Name
1199.15.61003 Boehringer Ingelheim Investigational Site
City
Southe Brisbane
State/Province
Queensland
Country
Australia
Facility Name
1199.15.61005 Boehringer Ingelheim Investigational Site
City
North Terrace
State/Province
South Australia
Country
Australia
Facility Name
1199.15.61007 Boehringer Ingelheim Investigational Site
City
Parkville
State/Province
Victoria
Country
Australia
Facility Name
1199.15.61002 Boehringer Ingelheim Investigational Site
City
Nedlands
State/Province
Western Australia
Country
Australia
Facility Name
1199.15.43003 Boehringer Ingelheim Investigational Site
City
Graz
Country
Austria
Facility Name
1199.15.43001 Boehringer Ingelheim Investigational Site
City
Innsbruck
Country
Austria
Facility Name
1199.15.43011 Boehringer Ingelheim Investigational Site
City
Krems
Country
Austria
Facility Name
1199.15.43007 Boehringer Ingelheim Investigational Site
City
Kufstein
Country
Austria
Facility Name
1199.15.43005 Boehringer Ingelheim Investigational Site
City
Linz
Country
Austria
Facility Name
1199.15.43010 Boehringer Ingelheim Investigational Site
City
Salzburg
Country
Austria
Facility Name
1199.15.43013 Boehringer Ingelheim Investigational Site
City
Wels
Country
Austria
Facility Name
1199.15.43002 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1199.15.43012 Boehringer Ingelheim Investigational Site
City
Wien
Country
Austria
Facility Name
1199.15.32010 Boehringer Ingelheim Investigational Site
City
Edegem
Country
Belgium
Facility Name
1199.15.32012 Boehringer Ingelheim Investigational Site
City
Hasselt
Country
Belgium
Facility Name
1199.15.32003 Boehringer Ingelheim Investigational Site
City
La Louvière
Country
Belgium
Facility Name
1199.15.32001 Boehringer Ingelheim Investigational Site
City
Leuven
Country
Belgium
Facility Name
1199.15.32007 Boehringer Ingelheim Investigational Site
City
Liège
Country
Belgium
Facility Name
1199.15.32008 Boehringer Ingelheim Investigational Site
City
Sint-Niklaas
Country
Belgium
Facility Name
1199.15.11005 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
1199.15.11004 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1199.15.11008 Boehringer Ingelheim Investigational Site
City
London
State/Province
Ontario
Country
Canada
Facility Name
1199.15.11009 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1199.15.11003 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1199.15.11006 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1199.15.11001 Boehringer Ingelheim Investigational Site
City
Sherbrooke
State/Province
Quebec
Country
Canada
Facility Name
1199.15.42002 Boehringer Ingelheim Investigational Site
City
Brno
Country
Czechia
Facility Name
1199.15.42003 Boehringer Ingelheim Investigational Site
City
Olomouc
Country
Czechia
Facility Name
1199.15.42001 Boehringer Ingelheim Investigational Site
City
Prague
Country
Czechia
Facility Name
1199.15.45004 Boehringer Ingelheim Investigational Site
City
Aalborg
Country
Denmark
Facility Name
1199.15.45002 Boehringer Ingelheim Investigational Site
City
Herlev
Country
Denmark
Facility Name
1199.15.45005 Boehringer Ingelheim Investigational Site
City
Herning
Country
Denmark
Facility Name
1199.15.45001 Boehringer Ingelheim Investigational Site
City
Købenahvn Ø
Country
Denmark
Facility Name
1199.15.45003 Boehringer Ingelheim Investigational Site
City
Odense C
Country
Denmark
Facility Name
1199.15.35801 Boehringer Ingelheim Investigational Site
City
Helsinki
Country
Finland
Facility Name
1199.15.35804 Boehringer Ingelheim Investigational Site
City
Jyväskylä
Country
Finland
Facility Name
1199.15.35805 Boehringer Ingelheim Investigational Site
City
Kuopio
Country
Finland
Facility Name
1199.15.35803 Boehringer Ingelheim Investigational Site
City
Oulu
Country
Finland
Facility Name
1199.15.35802 Boehringer Ingelheim Investigational Site
City
Tampere
Country
Finland
Facility Name
1199.15.33047 Boehringer Ingelheim Investigational Site
City
Aix-en-Provence
Country
France
Facility Name
1199.15.33035 Boehringer Ingelheim Investigational Site
City
Avignon cedex 02
Country
France
Facility Name
1199.15.33055 Boehringer Ingelheim Investigational Site
City
Besançon
Country
France
Facility Name
1199.15.33003 Boehringer Ingelheim Investigational Site
City
Bordeaux cedex
Country
France
Facility Name
1199.15.33004 Boehringer Ingelheim Investigational Site
City
Bordeaux
Country
France
Facility Name
1199.15.33006 Boehringer Ingelheim Investigational Site
City
Caen cedex 5
Country
France
Facility Name
1199.15.33025 Boehringer Ingelheim Investigational Site
City
Clermont-Ferrand cedex
Country
France
Facility Name
1199.15.33048 Boehringer Ingelheim Investigational Site
City
Dechy
Country
France
Facility Name
1199.15.33042 Boehringer Ingelheim Investigational Site
City
Fréjus
Country
France
Facility Name
1199.15.33037 Boehringer Ingelheim Investigational Site
City
La Roche-Sur-Yon cedex 09
Country
France
Facility Name
1199.15.33008 Boehringer Ingelheim Investigational Site
City
Le Mans
Country
France
Facility Name
1199.15.33009 Boehringer Ingelheim Investigational Site
City
Lille cedex
Country
France
Facility Name
1199.15.33020 Boehringer Ingelheim Investigational Site
City
Lyon
Country
France
Facility Name
1199.15.33011 Boehringer Ingelheim Investigational Site
City
Marseille cedex 09
Country
France
Facility Name
1199.15.33021 Boehringer Ingelheim Investigational Site
City
Monaco Cedex
Country
France
Facility Name
1199.15.33012 Boehringer Ingelheim Investigational Site
City
Mont-de-Marsan cedex
Country
France
Facility Name
1199.15.33052 Boehringer Ingelheim Investigational Site
City
Montpellier cedex 5
Country
France
Facility Name
1199.15.33053 Boehringer Ingelheim Investigational Site
City
Mougins
Country
France
Facility Name
1199.15.33038 Boehringer Ingelheim Investigational Site
City
Nancy
Country
France
Facility Name
1199.15.33013 Boehringer Ingelheim Investigational Site
City
Nantes cedex 02
Country
France
Facility Name
1199.15.33015 Boehringer Ingelheim Investigational Site
City
Orléans cedex 02
Country
France
Facility Name
1199.15.33027 Boehringer Ingelheim Investigational Site
City
Paris cedex 20
Country
France
Facility Name
1199.15.33001 Boehringer Ingelheim Investigational Site
City
Paris
Country
France
Facility Name
1199.15.33051 Boehringer Ingelheim Investigational Site
City
PERIGUEUX Cedex
Country
France
Facility Name
1199.15.33030 Boehringer Ingelheim Investigational Site
City
Plerin SUR MER
Country
France
Facility Name
1199.15.33045 Boehringer Ingelheim Investigational Site
City
Saint Cloud
Country
France
Facility Name
1199.15.33033 Boehringer Ingelheim Investigational Site
City
Saint-Herblain cedex
Country
France
Facility Name
1199.15.33018 Boehringer Ingelheim Investigational Site
City
Strasbourg cedex
Country
France
Facility Name
1199.15.33039 Boehringer Ingelheim Investigational Site
City
Thonon-Les-Bains
Country
France
Facility Name
1199.15.33031 Boehringer Ingelheim Investigational Site
City
Vandoeuvre les Nancy cedex
Country
France
Facility Name
1199.15.33050 Boehringer Ingelheim Investigational Site
City
Villejuif Cedex
Country
France
Facility Name
1199.15.49040 Boehringer Ingelheim Investigational Site
City
Aachen
Country
Germany
Facility Name
1199.15.49070 Boehringer Ingelheim Investigational Site
City
Aalen
Country
Germany
Facility Name
1199.15.49086 Boehringer Ingelheim Investigational Site
City
Aschaffenburg
Country
Germany
Facility Name
1199.15.49002 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1199.15.49039 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1199.15.49041 Boehringer Ingelheim Investigational Site
City
Berlin
Country
Germany
Facility Name
1199.15.49004 Boehringer Ingelheim Investigational Site
City
Bonn
Country
Germany
Facility Name
1199.15.49042 Boehringer Ingelheim Investigational Site
City
Bonn
Country
Germany
Facility Name
1199.15.49071 Boehringer Ingelheim Investigational Site
City
Bottrop
Country
Germany
Facility Name
1199.15.49081 Boehringer Ingelheim Investigational Site
City
Böblingen
Country
Germany
Facility Name
1199.15.49043 Boehringer Ingelheim Investigational Site
City
Chemnitz
Country
Germany
Facility Name
1199.15.49005 Boehringer Ingelheim Investigational Site
City
Dessau
Country
Germany
Facility Name
1199.15.49006 Boehringer Ingelheim Investigational Site
City
Detmold
Country
Germany
Facility Name
1199.15.49007 Boehringer Ingelheim Investigational Site
City
Dresden
Country
Germany
Facility Name
1199.15.49067 Boehringer Ingelheim Investigational Site
City
Dresden
Country
Germany
Facility Name
1199.15.49008 Boehringer Ingelheim Investigational Site
City
Düsseldorf
Country
Germany
Facility Name
1199.15.49009 Boehringer Ingelheim Investigational Site
City
Ebersberg
Country
Germany
Facility Name
1199.15.49010 Boehringer Ingelheim Investigational Site
City
Essen
Country
Germany
Facility Name
1199.15.49066 Boehringer Ingelheim Investigational Site
City
Essen
Country
Germany
Facility Name
1199.15.49089 Boehringer Ingelheim Investigational Site
City
Essen
Country
Germany
Facility Name
1199.15.49045 Boehringer Ingelheim Investigational Site
City
Frankfurt
Country
Germany
Facility Name
1199.15.49011 Boehringer Ingelheim Investigational Site
City
Freiburg
Country
Germany
Facility Name
1199.15.49068 Boehringer Ingelheim Investigational Site
City
Freiburg
Country
Germany
Facility Name
1199.15.49083 Boehringer Ingelheim Investigational Site
City
Freudenstadt
Country
Germany
Facility Name
1199.15.49046 Boehringer Ingelheim Investigational Site
City
Fulda
Country
Germany
Facility Name
1199.15.49012 Boehringer Ingelheim Investigational Site
City
Fürstenfeldbruck
Country
Germany
Facility Name
1199.15.49064 Boehringer Ingelheim Investigational Site
City
Greifswald
Country
Germany
Facility Name
1199.15.49076 Boehringer Ingelheim Investigational Site
City
Gütersloh
Country
Germany
Facility Name
1199.15.49014 Boehringer Ingelheim Investigational Site
City
Halle/S.
Country
Germany
Facility Name
1199.15.49015 Boehringer Ingelheim Investigational Site
City
Hamburg
Country
Germany
Facility Name
1199.15.49084 Boehringer Ingelheim Investigational Site
City
Hamburg
Country
Germany
Facility Name
1199.15.49073 Boehringer Ingelheim Investigational Site
City
Hanau
Country
Germany
Facility Name
1199.15.49095 Boehringer Ingelheim Investigational Site
City
Heidelberg
Country
Germany
Facility Name
1199.15.49080 Boehringer Ingelheim Investigational Site
City
Henstedt-Ulzburg
Country
Germany
Facility Name
1199.15.49047 Boehringer Ingelheim Investigational Site
City
Hildesheim
Country
Germany
Facility Name
1199.15.49016 Boehringer Ingelheim Investigational Site
City
Karlsruhe
Country
Germany
Facility Name
1199.15.49017 Boehringer Ingelheim Investigational Site
City
Kiel
Country
Germany
Facility Name
1199.15.49062 Boehringer Ingelheim Investigational Site
City
Krefeld
Country
Germany
Facility Name
1199.15.49018 Boehringer Ingelheim Investigational Site
City
Landshut
Country
Germany
Facility Name
1199.15.49087 Boehringer Ingelheim Investigational Site
City
Ludwigsburg
Country
Germany
Facility Name
1199.15.49019 Boehringer Ingelheim Investigational Site
City
Lübeck
Country
Germany
Facility Name
1199.15.49020 Boehringer Ingelheim Investigational Site
City
Magdeburg
Country
Germany
Facility Name
1199.15.49021 Boehringer Ingelheim Investigational Site
City
Mainz
Country
Germany
Facility Name
1199.15.49022 Boehringer Ingelheim Investigational Site
City
Mainz
Country
Germany
Facility Name
1199.15.49023 Boehringer Ingelheim Investigational Site
City
Mannheim
Country
Germany
Facility Name
1199.15.49024 Boehringer Ingelheim Investigational Site
City
Marburg
Country
Germany
Facility Name
1199.15.49025 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1199.15.49026 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1199.15.49027 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1199.15.49048 Boehringer Ingelheim Investigational Site
City
München
Country
Germany
Facility Name
1199.15.49065 Boehringer Ingelheim Investigational Site
City
Neumarkt i.d.Opf.
Country
Germany
Facility Name
1199.15.49029 Boehringer Ingelheim Investigational Site
City
Offenbach
Country
Germany
Facility Name
1199.15.49082 Boehringer Ingelheim Investigational Site
City
Paderborn
Country
Germany
Facility Name
1199.15.49030 Boehringer Ingelheim Investigational Site
City
Radebeul
Country
Germany
Facility Name
1199.15.49061 Boehringer Ingelheim Investigational Site
City
Ravensburg
Country
Germany
Facility Name
1199.15.49050 Boehringer Ingelheim Investigational Site
City
Regensburg
Country
Germany
Facility Name
1199.15.49051 Boehringer Ingelheim Investigational Site
City
Rosenheim
Country
Germany
Facility Name
1199.15.49052 Boehringer Ingelheim Investigational Site
City
Rostock
Country
Germany
Facility Name
1199.15.49054 Boehringer Ingelheim Investigational Site
City
Saalfeld
Country
Germany
Facility Name
1199.15.49031 Boehringer Ingelheim Investigational Site
City
Salzgitter
Country
Germany
Facility Name
1199.15.49055 Boehringer Ingelheim Investigational Site
City
Solingen
Country
Germany
Facility Name
1199.15.49092 Boehringer Ingelheim Investigational Site
City
Stadthagen
Country
Germany
Facility Name
1199.15.49063 Boehringer Ingelheim Investigational Site
City
Stendal
Country
Germany
Facility Name
1199.15.49093 Boehringer Ingelheim Investigational Site
City
Stralsund
Country
Germany
Facility Name
1199.15.49033 Boehringer Ingelheim Investigational Site
City
Stuttgart
Country
Germany
Facility Name
1199.15.49056 Boehringer Ingelheim Investigational Site
City
Stuttgart
Country
Germany
Facility Name
1199.15.49090 Boehringer Ingelheim Investigational Site
City
Stuttgart
Country
Germany
Facility Name
1199.15.49079 Boehringer Ingelheim Investigational Site
City
Suhl
Country
Germany
Facility Name
1199.15.49034 Boehringer Ingelheim Investigational Site
City
Traunstein
Country
Germany
Facility Name
1199.15.49057 Boehringer Ingelheim Investigational Site
City
Trier
Country
Germany
Facility Name
1199.15.49035 Boehringer Ingelheim Investigational Site
City
Tübingen
Country
Germany
Facility Name
1199.15.49058 Boehringer Ingelheim Investigational Site
City
Ulm
Country
Germany
Facility Name
1199.15.49085 Boehringer Ingelheim Investigational Site
City
Viersen
Country
Germany
Facility Name
1199.15.49001 Boehringer Ingelheim Investigational Site
City
Wiesbaden
Country
Germany
Facility Name
1199.15.49036 Boehringer Ingelheim Investigational Site
City
Wiesbaden
Country
Germany
Facility Name
1199.15.49059 Boehringer Ingelheim Investigational Site
City
Witten
Country
Germany
Facility Name
1199.15.49037 Boehringer Ingelheim Investigational Site
City
Wolfsburg
Country
Germany
Facility Name
1199.15.49060 Boehringer Ingelheim Investigational Site
City
Worms
Country
Germany
Facility Name
1199.15.30001 Boehringer Ingelheim Investigational Site
City
Athens
Country
Greece
Facility Name
1199.15.30003 Boehringer Ingelheim Investigational Site
City
Heraklio
Country
Greece
Facility Name
1199.15.30002 Boehringer Ingelheim Investigational Site
City
Nea Kifisia
Country
Greece
Facility Name
1199.15.30005 Boehringer Ingelheim Investigational Site
City
Patras
Country
Greece
Facility Name
1199.15.30004 Boehringer Ingelheim Investigational Site
City
Thessaloniki
Country
Greece
Facility Name
1199.15.39027 Boehringer Ingelheim Investigational Site
City
Asti
Country
Italy
Facility Name
1199.15.39002 Boehringer Ingelheim Investigational Site
City
Avellino
Country
Italy
Facility Name
1199.15.39003 Boehringer Ingelheim Investigational Site
City
Aviano (pn)
Country
Italy
Facility Name
1199.15.39004 Boehringer Ingelheim Investigational Site
City
Bari
Country
Italy
Facility Name
1199.15.39005 Boehringer Ingelheim Investigational Site
City
Benevento
Country
Italy
Facility Name
1199.15.39029 Boehringer Ingelheim Investigational Site
City
Brescia
Country
Italy
Facility Name
1199.15.39040 Boehringer Ingelheim Investigational Site
City
Catania
Country
Italy
Facility Name
1199.15.39007 Boehringer Ingelheim Investigational Site
City
Catanzaro
Country
Italy
Facility Name
1199.15.39008 Boehringer Ingelheim Investigational Site
City
Faenza (RA)
Country
Italy
Facility Name
1199.15.39039 Boehringer Ingelheim Investigational Site
City
Ferrara
Country
Italy
Facility Name
1199.15.39017 Boehringer Ingelheim Investigational Site
City
Genova
Country
Italy
Facility Name
1199.15.39037 Boehringer Ingelheim Investigational Site
City
Lecce
Country
Italy
Facility Name
1199.15.39009 Boehringer Ingelheim Investigational Site
City
Mantova
Country
Italy
Facility Name
1199.15.39033 Boehringer Ingelheim Investigational Site
City
Meldola (fc)
Country
Italy
Facility Name
1199.15.39021 Boehringer Ingelheim Investigational Site
City
Milano
Country
Italy
Facility Name
1199.15.39028 Boehringer Ingelheim Investigational Site
City
Milano
Country
Italy
Facility Name
1199.15.39036 Boehringer Ingelheim Investigational Site
City
Milano
Country
Italy
Facility Name
1199.15.39010 Boehringer Ingelheim Investigational Site
City
Modena
Country
Italy
Facility Name
1199.15.39026 Boehringer Ingelheim Investigational Site
City
Monza
Country
Italy
Facility Name
1199.15.39001 Boehringer Ingelheim Investigational Site
City
Napoli
Country
Italy
Facility Name
1199.15.39022 Boehringer Ingelheim Investigational Site
City
Padova
Country
Italy
Facility Name
1199.15.39011 Boehringer Ingelheim Investigational Site
City
Palermo
Country
Italy
Facility Name
1199.15.39031 Boehringer Ingelheim Investigational Site
City
Palermo
Country
Italy
Facility Name
1199.15.39023 Boehringer Ingelheim Investigational Site
City
Pisa
Country
Italy
Facility Name
1199.15.39012 Boehringer Ingelheim Investigational Site
City
Pordenone
Country
Italy
Facility Name
1199.15.39024 Boehringer Ingelheim Investigational Site
City
Reggio Emilia
Country
Italy
Facility Name
1199.15.39013 Boehringer Ingelheim Investigational Site
City
Roma
Country
Italy
Facility Name
1199.15.39014 Boehringer Ingelheim Investigational Site
City
Roma
Country
Italy
Facility Name
1199.15.39034 Boehringer Ingelheim Investigational Site
City
Rozzano (MI)
Country
Italy
Facility Name
1199.15.39030 Boehringer Ingelheim Investigational Site
City
San Fermo Della Battaglia
Country
Italy
Facility Name
1199.15.39018 Boehringer Ingelheim Investigational Site
City
Sondrio
Country
Italy
Facility Name
1199.15.39006 Boehringer Ingelheim Investigational Site
City
Tappino (CB)
Country
Italy
Facility Name
1199.15.39019 Boehringer Ingelheim Investigational Site
City
Torino
Country
Italy
Facility Name
1199.15.39020 Boehringer Ingelheim Investigational Site
City
Torino
Country
Italy
Facility Name
1199.15.39032 Boehringer Ingelheim Investigational Site
City
Varese
Country
Italy
Facility Name
1199.15.31009 Boehringer Ingelheim Investigational Site
City
's-HERTOGENBOSCH
Country
Netherlands
Facility Name
1199.15.31005 Boehringer Ingelheim Investigational Site
City
Amersfoort
Country
Netherlands
Facility Name
1199.15.31004 Boehringer Ingelheim Investigational Site
City
Niewegein
Country
Netherlands
Facility Name
1199.15.31003 Boehringer Ingelheim Investigational Site
City
Nijmegen
Country
Netherlands
Facility Name
1199.15.31006 Boehringer Ingelheim Investigational Site
City
Rotterdam
Country
Netherlands
Facility Name
1199.15.31002 Boehringer Ingelheim Investigational Site
City
Utrecht
Country
Netherlands
Facility Name
1199.15.47003 Boehringer Ingelheim Investigational Site
City
Bergen
Country
Norway
Facility Name
1199.15.47001 Boehringer Ingelheim Investigational Site
City
Oslo
Country
Norway
Facility Name
1199.15.47002 Boehringer Ingelheim Investigational Site
City
Stavanger
Country
Norway
Facility Name
1199.15.47004 Boehringer Ingelheim Investigational Site
City
Trondheim
Country
Norway
Facility Name
1199.15.48003 Boehringer Ingelheim Investigational Site
City
Gdansk
Country
Poland
Facility Name
1199.15.48006 Boehringer Ingelheim Investigational Site
City
Lublin
Country
Poland
Facility Name
1199.15.48001 Boehringer Ingelheim Investigational Site
City
Warszawa
Country
Poland
Facility Name
1199.15.35102 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1199.15.35104 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1199.15.35101 Instituto Portugues de Oncologia Lisboa Francisco Gentil
City
Lisboa
Country
Portugal
Facility Name
1199.15.35106 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1199.15.35108 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1199.15.35105 Boehringer Ingelheim Investigational Site
City
Porto
Country
Portugal
Facility Name
1199.15.35109 Boehringer Ingelheim Investigational Site
City
Vila Real
Country
Portugal
Facility Name
1199.15.70006 Boehringer Ingelheim Investigational Site
City
Barnaul
Country
Russian Federation
Facility Name
1199.15.70005 Boehringer Ingelheim Investigational Site
City
Ekaterinburg
Country
Russian Federation
Facility Name
1199.15.70007 Boehringer Ingelheim Investigational Site
City
Kazan
Country
Russian Federation
Facility Name
1199.15.70001 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1199.15.70002 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1199.15.42101 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1199.15.42105 Boehringer Ingelheim Investigational Site
City
Bratislava
Country
Slovakia
Facility Name
1199.15.42106 Boehringer Ingelheim Investigational Site
City
Kosice
Country
Slovakia
Facility Name
1199.15.42103 Boehringer Ingelheim Investigational Site
City
Nitra
Country
Slovakia
Facility Name
1199.15.42104 Boehringer Ingelheim Investigational Site
City
Poprad
Country
Slovakia
Facility Name
1199.15.42102 Boehringer Ingelheim Investigational Site
City
Zilina
Country
Slovakia
Facility Name
1199.15.34001 Boehringer Ingelheim Investigational Site
City
Badalona
Country
Spain
Facility Name
1199.15.34003 Boehringer Ingelheim Investigational Site
City
Barcelona
Country
Spain
Facility Name
1199.15.34006 Boehringer Ingelheim Investigational Site
City
Girona
Country
Spain
Facility Name
1199.15.34004 Boehringer Ingelheim Investigational Site
City
Lleida
Country
Spain
Facility Name
1199.15.34002 Boehringer Ingelheim Investigational Site
City
Madrid
Country
Spain
Facility Name
1199.15.34010 Boehringer Ingelheim Investigational Site
City
Madrid
Country
Spain
Facility Name
1199.15.34005 Boehringer Ingelheim Investigational Site
City
Palma de Mallorca
Country
Spain
Facility Name
1199.15.34009 Boehringer Ingelheim Investigational Site
City
Valencia
Country
Spain
Facility Name
1199.15.46005 Boehringer Ingelheim Investigational Site
City
Linköping
Country
Sweden
Facility Name
1199.15.46001 Boehringer Ingelheim Investigational Site
City
Lund
Country
Sweden
Facility Name
1199.15.46002 Boehringer Ingelheim Investigational Site
City
Stockholm
Country
Sweden
Facility Name
1199.15.46004 Boehringer Ingelheim Investigational Site
City
Umeå
Country
Sweden
Facility Name
1199.15.46003 Boehringer Ingelheim Investigational Site
City
Uppsala
Country
Sweden
Facility Name
1199.15.38006 Boehringer Ingelheim Investigational Site
City
Cherkasy
Country
Ukraine
Facility Name
1199.15.38005 Boehringer Ingelheim Investigational Site
City
Dnepropetrovsk
Country
Ukraine
Facility Name
1199.15.38004 Boehringer Ingelheim Investigational Site
City
Donetsk
Country
Ukraine
Facility Name
1199.15.38002 Boehringer Ingelheim Investigational Site
City
Kharkiv
Country
Ukraine
Facility Name
1199.15.38003 Boehringer Ingelheim Investigational Site
City
Lviv
Country
Ukraine
Facility Name
1199.15.44006 Boehringer Ingelheim Investigational Site
City
Derby
Country
United Kingdom
Facility Name
1199.15.44007 Boehringer Ingelheim Investigational Site
City
Dundee
Country
United Kingdom
Facility Name
1199.15.44003 Boehringer Ingelheim Investigational Site
City
Glasgow
Country
United Kingdom
Facility Name
1199.15.44001 Boehringer Ingelheim Investigational Site
City
Guildford
Country
United Kingdom
Facility Name
1199.15.44005 Boehringer Ingelheim Investigational Site
City
London
Country
United Kingdom
Facility Name
1199.15.44004 Boehringer Ingelheim Investigational Site
City
Nottingham
Country
United Kingdom
Facility Name
1199.15.44002 Boehringer Ingelheim Investigational Site
City
Poole
Country
United Kingdom
Facility Name
1199.15.44008 Boehringer Ingelheim Investigational Site
City
Truro
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
26590673
Citation
du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidzinski M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjorge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com
Description
Related Info

Learn more about this trial

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

We'll reach out to this number within 24 hrs